TTP4488 Phase II Trial company gets funding
WRAL Local Tech Wire: business, technology, biotechnology, and venture capital news from across the southeastern region: "Privately held TransTech Pharma has landed a drug development deal worth at least $155 million with Pfizer.
Pfizer is also pumping $18 million into TransTech for expansion of its drug research capabilities.
The two companies are teaming up to pursue development of TransTech compounds that could combat Alzheimer’s disease.
TransTech’s TTP488 compound is currently being tested in a Phase II clinical study of Alzheimer’s patients. Its TTP4000 compound is expected to enter clinical trial before the end of 2006."
Pfizer is also pumping $18 million into TransTech for expansion of its drug research capabilities.
The two companies are teaming up to pursue development of TransTech compounds that could combat Alzheimer’s disease.
TransTech’s TTP488 compound is currently being tested in a Phase II clinical study of Alzheimer’s patients. Its TTP4000 compound is expected to enter clinical trial before the end of 2006."
0 Comments:
Post a Comment
<< Home